Skip to main content
SpringerLink
Log in

Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments

  • Chapter
Book cover Molecular Autoimmunity

  • 483 Accesses

11. Conclusions

The use of TNFα inhibitors has provided clear evidence for the direct role of cytokines in complex inflammatory diseases. The simplest approach, already in practice, is the specific inhibition of their action. The stimulation of endogenous regulatory mechanisms can represent a more physiological way to restore an adequate balance. The lack of response and the occurrence of adverse reactions observed in some patients exposed to cytokines and their inhibitors imply taking into account the level of production and regulation of the target cytokines. Part of such heterogeneity is genetically determined. Considering these issues will allow a better risk-benefit assessment of the treatment for each patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney, A.L. (2003). Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem., 278, 1910–1914.

    Article  CAS  PubMed  Google Scholar 

  • Agnello, V., Chung, R.T., and Kaplan, L.M. (1992). A role for hepatitis C virus infection in type II cryoglobulinemia. N. Engl. J. Med., 327, 1490–1495.

    CAS  PubMed  Google Scholar 

  • Arend, W.P. and Dayer, J.M. (1995). Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum., 38, 151–160.

    CAS  PubMed  Google Scholar 

  • Baert, F., Noman, M., Vermeire, S., Van Assche, G., D’Haens, G. Carbonez, A., and Rutgeerts, P. (2003). Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med., 348, 601–608.

    Article  CAS  PubMed  Google Scholar 

  • Ballmer-Weber, B.K., Dummer, R., Kung, E., Burg, G., and Ballmer, P.E. (1995). Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br. J. Cancer, 71, 78–82.

    CAS  PubMed  Google Scholar 

  • Batisse, D., Karmochkine, M., Jacquot, C., Kazatchkine, M.D., and Weiss, L. (2004). Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur. J. Gastroenterol. Hepatol., 16, 701–703.

    CAS  PubMed  Google Scholar 

  • Batocchi, A.P., Evoli, A., Servidei, S., Palmisani, M.T., Apollo, F., and Tonali, P. (1995). Myasthenia gravis during interferon alfa therapy. Neurology, 45, 382–383.

    CAS  PubMed  Google Scholar 

  • Bresnihan, B. (2002). Anakinra as a new therapeutic option in rheumatoid arthritis: Clinical results and perspectives. Clin. Exp. Rheumatol., 20, S32–S34.

    CAS  PubMed  Google Scholar 

  • Brown, S.L., Greene, M.H., Gershon, S.K., Edwards, E.T., and Braun, M.M. (2002). Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum., 46, 3151–3158.

    Article  CAS  PubMed  Google Scholar 

  • Burger, D. and Dayer, J.M. (2002). Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-alpha production in contact-mediated activation of monocytes by T lymphocytes. Ann. NY Acad. Sci., 966, 464–473.

    CAS  PubMed  Google Scholar 

  • Cannon, G.W., Emkey, R.D., Denes, A., Cohen, S.A., Saway, P.A., Wolfe, F., Jaffer, A.M., Weaver, A.L., Manaster, B.J., and McCarthy, K.A. (1993). Prospective 5-year followup of recombinant interferon-gamma in rheumatoid arthritis. J. Rheumatol., 20, 1867–1873.

    CAS  PubMed  Google Scholar 

  • Carmona, L., Hernandez-Garcia, C., Vadillo, C., Pato, E., Balsa, A., Gonzalez-Alvaro, I., Belmonte, M.A., Tena, X., and Sanmarti, R. (2003). Increased risk of tuberculosis in patients with rheumatoid arthritis. J. Rheumatol., 30, 1436–1439.

    PubMed  Google Scholar 

  • Casanova, J.L. and Abel, L. (2002). Genetic dissection of immunity to mycobacteria: The human model. Annu. Rev. Immunol., 20, 581–620.

    Article  CAS  PubMed  Google Scholar 

  • Cebon, J., Jager, E., Shackleton, M.J., Gibbs, P., Davis, I.D., Hopkins, W., Gibbs, S., Chen, Q., Karbach, J., Jackson, H., MacGregor, D.P., Sturrock, S., Vaughan, H., Maraskovsky, E., Neumann, A., Hoffman, E., Sherman, M.L., and Knuth, A. (2003). Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun., 3, 7.

    PubMed  Google Scholar 

  • Chabaud, M. and Miossec, P. (2001). The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum., 44, 1293–1303.

    Article  CAS  PubMed  Google Scholar 

  • Conlon, K.C., Urba, W.J., Smith, J.W., 2nd, Steis, R.G., Longo, D.L., and Clark, J.W. (1990). Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer, 65, 2237–2242.

    CAS  PubMed  Google Scholar 

  • Fattovich, G., Betterle, C., Brollo, L., Pedini, B., Giustina, G., Realdi, G., Alberti, A., and Ruol, A. (1991). Autoantibodies during alpha-interferon therapy for chronic hepatitis B. J. Med. Virol., 34, 132–135.

    CAS  PubMed  Google Scholar 

  • Fattovich, G., Giustina, G., Favarato, S., and Ruol, A. (1996). A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J. Hepatol., 24, 38–47.

    Article  CAS  PubMed  Google Scholar 

  • Feldmann, M. and Maini, R.N. (2001). Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu. Rev. Immunol., 19, 163–196.

    Article  CAS  PubMed  Google Scholar 

  • Ferri, C., Marzo, E., Longombardo, G., Lombardini, F., La Civita, L., Vanacore, R., Liberati, A.M., Gerli, R., Greco, F., Moretti, A. (1993). Interferon-alpha in mixed cryoglobulinemia patients: A randomized, crossover-controlled trial. Blood, 81, 1132–1136.

    CAS  PubMed  Google Scholar 

  • Francis, G. (2004). Benefit-risk assessment of interferon-beta therapy for relapsing multiple sclerosis. Expert Opin. Drug Saf., 3, 289–303.

    Article  CAS  PubMed  Google Scholar 

  • Gaspari, A.A. (1994). Autoimmunity as a complication of interleukin 2 immunotherapy. Many unanswered questions. Arch. Dermatol., 130, 894–898.

    Article  CAS  PubMed  Google Scholar 

  • Genovese, M.C., Cohen, S., Moreland, L., Lium, D., Robbins, S., Newmark, R., and Bekker, P. (2004). Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum., 50, 1412–1419.

    Article  CAS  PubMed  Google Scholar 

  • Granet, C., Maslinski, W., and Miossec, P. (2004). Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. Arthritis Res. Ther., 6, R190–R198.

    Article  CAS  PubMed  Google Scholar 

  • Granet, C. and Miossec, P. (2004). Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. Cytokine, 26, 169–177.

    Article  CAS  PubMed  Google Scholar 

  • Haddad, J., Deny, P., Munz-Gotheil, C., Ambrosini, J.C., Trinchet, J.C., Pateron, D., Mal, F., Callard, P., and Beaugrand, M. (1992). Lymphocytic sialadenitis of Sjögren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet, 339, 321–323.

    Article  CAS  PubMed  Google Scholar 

  • Hjelmstrom, P., Fjell, J., Nakagawa, T., Sacca, R., Cuff, C.A., and Ruddle, N.H. (2000). Lymphoid tissue homing chemokines are expressed in chronic inflammation. Am. J. Pathol., 156, 1133–1138.

    CAS  PubMed  Google Scholar 

  • Hoshina, Y., Moriuchi, J., Nakamura, Y., Arimori, S., and Ichikawa, Y. (1994). CD4+ T cell-mediated leukopenia of Felty’s syndrome successfully treated with granulocyte-colony-stimulating factor and methotrexate. Arthritis Rheum., 37, 298–299.

    CAS  PubMed  Google Scholar 

  • Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., Nishimoto, N., Yoshizaki, K., Shimoyama, T., and Kishimoto, T. (2004). A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology, 126, 989–996.

    Article  CAS  PubMed  Google Scholar 

  • Kawashima, M. and Miossec, P. (2003). Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum., 48, 631–637.

    Article  CAS  PubMed  Google Scholar 

  • Kawashima, M. and Miossec, P. (2004). Decreased response to IL-12 and IL-18 of blood cells in rheumatoid arthritis. Arthritis Res. Ther., 6, R39–R45.

    Article  CAS  PubMed  Google Scholar 

  • Kawashima, M., Novick, D., Rubinstein, M., and Miossec, P. (2004). Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis. Arthritis Rheum., 50, 1800–1805.

    Article  CAS  PubMed  Google Scholar 

  • Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D., Siegel, J.N., and Braun, M.M. (2001). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med., 345, 1098–1104.

    Article  CAS  PubMed  Google Scholar 

  • Kiely, P.D. and Bruckner, F.E. (1994). Acute arthritis following interferon-alpha therapy. Br. J. Rheumatol., 33, 502–503.

    CAS  PubMed  Google Scholar 

  • Kontoyiannis, D. and Kollias, G. (2000). Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol., 30, 2038–2047.

    Article  CAS  PubMed  Google Scholar 

  • Lisker-Melman, M., Di Bisceglie, A.M., Usala, S.J., Weintraub, B., Murray, L.M., and Hoofnagle, J.H. (1992). Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology, 102, 2155–2160.

    CAS  PubMed  Google Scholar 

  • Llorente, L., Zou, W., Levy, Y., Richaud-Patin, Y., Wijdenes, J., Alcocer-Varela, J., Morel-Fourrier, B., Brouet, J.C., Alarcon-Segovia, D., Galanaud, P. (1995). Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med., 181, 839–844.

    Article  CAS  PubMed  Google Scholar 

  • Marotte, H., Charrin, J.E., and Miossec, P. (2001). Infliximab-induced aseptic meningitis. Lancet, 358, 1784.

    Article  CAS  PubMed  Google Scholar 

  • Mazzaro, C., Zorat, F., Comar, C., Nascimben, F., Bianchini, D., Baracetti, S., Donada, C., Donadon, V., and Pozzato, G. (2003). Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J. Rheumatol., 30, 1775–1781.

    CAS  PubMed  Google Scholar 

  • McInnes, I.B. and Gracie, J.A. (2004). Interleukin-15: A new cytokine target for the treatment of inflammatory diseases. Curr. Opin. Pharmacol., 4, 392–397.

    CAS  PubMed  Google Scholar 

  • McLachlan, J.B., Hart, J.P., Pizzo, S.V., Shelburne, C.P., Staats, H.F., Gunn, M.D., and Abraham, S.N. (2003). Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat. Immunol., 4, 1199–1205.

    Article  CAS  PubMed  Google Scholar 

  • Miossec, P. (1997). Cytokine-induced autoimmune disorders. Drug Saf., 17, 93–104.

    CAS  PubMed  Google Scholar 

  • Miossec, P. (2003). Interleukin-17 in rheumatoid arthritis: If T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum., 48, 594–601.

    Article  CAS  PubMed  Google Scholar 

  • Miossec, P. and van den Berg, W. (1997). Th1/Th2 cytokine balance in arthritis. Arthritis Rheum., 40, 2105–2115.

    CAS  PubMed  Google Scholar 

  • Mohan, N., Edwards, E.T., Cupps, T.R., Oliverio, P.J., Sandberg, G., Crayton, H., Richert, J.R., and Siegel, J.N. (2001). Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum., 44, 2862–2869.

    Article  CAS  PubMed  Google Scholar 

  • Mugnier, B., Balandraud, N., Darque, A., Roudier, C., Roudier, J., and Reviron, D. (2003). Polymorphism at position −308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum., 48, 1849–1852.

    Article  CAS  PubMed  Google Scholar 

  • Murakami, C.S., Zeller, K., Bodenheimer, H.C., Jr., and Lee, W.M. (1994). Idiopathic thrombocytopenic purpura during interferon-alpha 2B treatment for chronic hepatitis. Am. J. Gastroenterol., 89, 2244–2245.

    CAS  PubMed  Google Scholar 

  • Nishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., Kishimoto, T., Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., and Shimoyama, T. (2004). Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum., 50, 1761–1769.

    Article  CAS  PubMed  Google Scholar 

  • Paleolog, E. (1997). Target effector role of vascular endothelium in the inflammatory response: Insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. Mol. Pathol., 50, 225–233.

    CAS  PubMed  Google Scholar 

  • Panitch, H.S., Hirsch, R.L., Haley, A.S., and Johnson, K.P. (1987). Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet, 1, 893–895.

    CAS  PubMed  Google Scholar 

  • Pascual, V., Banchereau, J., and Palucka, A.K. (2003). The central role of dendritic cells and interferon-alpha in SLE. Curr. Opin. Rheumatol., 15, 548–556.

    CAS  PubMed  Google Scholar 

  • Riddell, L.A., Pinching, A.J., Hill, S., Ng, T.T., Arbe, E., Lapham, G.P., Ash, S., Hillman, R., Tchamouroff, S., Denning, D.W., and Parkin, J.M. (2001). A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res. Hum. Retroviruses, 17, 789–797.

    Article  CAS  PubMed  Google Scholar 

  • Robinson, W.H., Genovese, M.C., and Moreland, L.W. (2001). Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum., 44, 1977–1983.

    Article  CAS  PubMed  Google Scholar 

  • Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med., 319, 1676–1680.

    CAS  PubMed  Google Scholar 

  • Ruddle, N.H. (1999). Lymphoid neo-organogenesis: Lymphotoxin’s role in inflammation and development. Immunol. Res., 19, 119–125.

    CAS  PubMed  Google Scholar 

  • Saab, S., Kalmaz, D., Gajjar, N.A., Hiatt, J., Durazo, F., Han, S., Farmer, D.G., Ghobrial, R.M., Yersiz, H., Goldstein, L.I., Lassman, C.R., and Busuttil, R.W. (2004). Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transplant., 10, 859–867.

    Article  Google Scholar 

  • Sangro, B., Mazzolini, G., Ruiz, J., Herraiz, M., Quiroga, J., Herrero, I., Benito, A., Larrache, J., Pueyo, J., Subtil, J.C., Olague, C., Sola, J., Sadaba, B., Lacasa, C., Melero, I., Qian, C., and Prieto, J. (2004). Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol., 22, 1389–1397.

    Article  CAS  PubMed  Google Scholar 

  • Schmidt, K.N. and Ouyang, W. (2004). Targeting interferon-alpha: A promising approach for systemic lupus erythematosus therapy. Lupus, 13, 348–352.

    Article  CAS  PubMed  Google Scholar 

  • Shakoor, N., Michalska, M., Harris, C.A., and Block, J.A. (2002). Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 359, 579–580.

    Article  CAS  PubMed  Google Scholar 

  • Shealy, D.J., Wooley, P.H., Emmell, E., Volk, A., Rosenberg, A., Treacy, G., Wagner, C.L., Mayton, L., Griswold, D.E., and Song, X.Y. (2002). Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res., 4, R7.

    Article  PubMed  Google Scholar 

  • Stricker, R.B., Barlogie, B., and Kiprov, D.D. (1994). Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J. Rheumatol., 21, 350–352.

    CAS  PubMed  Google Scholar 

  • Stuart, K., Levy, D.E., Anderson, T., Axiotis, C.A., Dutcher, J.P., Eisenberg, A., Erban, J.K., and Benson, I.A. (2004). Phase II study of interferon gamma in malignant carcinoid tumors (E9292): A trial of the Eastern Cooperative Oncology Group. Invest. New Drugs, 22, 75–81.

    Article  CAS  PubMed  Google Scholar 

  • Tak, P.P., Taylor, P.C., Breedveld, F.C., Smeets, T.J., Daha, M.R., Kluin, P.M., Meinders, A.E., and Maini, R.N. (1996). Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum., 39, 1077–1081.

    CAS  PubMed  Google Scholar 

  • Trinchieri, G., Pflanz, S., and Kastelein, R.A. (2003). The IL-12 family of heterodimeric cytokines: New players in the regulation of T cell responses. Immunity, 19, 641–644.

    Article  CAS  PubMed  Google Scholar 

  • Ulfgren, A.K., Andersson, U., Engstrom, M., Klareskog, L., Maini, R.N., and Taylor, P.C. (2000). Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum., 43, 2391–2396.

    Article  CAS  PubMed  Google Scholar 

  • Van Assche, G. and Rutgeerts, P. (2000). Anti-TNF agents in Crohn’s disease. Expert Opin. Invest. Drugs, 9, 103–111.

    Article  Google Scholar 

  • Van den Berg, W.B. (2002). Lessons from animal models of arthritis. Curr. Rheumatol. Rep., 4, 232–239.

    PubMed  Google Scholar 

  • Van den Brande, J.M., Braat, H., van den Brink, G.R., Versteeg, H.H., Bauer, C.A., Hoedemaeker, I., van Montfrans, C., Hommes, D.W., Peppelenbosch, M.P., and van Deventer, S.J. (2003). Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology, 124, 1774–1785.

    PubMed  Google Scholar 

  • Wilson, L.E., Widman, D., Dikman, S.H., and Gorevic, P.D. (2002). Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum., 32, 163–173.

    Article  PubMed  Google Scholar 

  • Yasuda, M., Kihara, T., Wada, T., Shiokawa, S., Furuta, E., Suenagu, Y., Nonaka, S., Nobunaga, M., Yoshiok, K., and Isayama, T. (1994). Granulocyte colony-stimulating factor induction of improved leukocytopenia with inflammatory flare in a Felty’s syndrome patient. Arthritis Rheum., 37, 145–146.

    CAS  PubMed  Google Scholar 

  • Ziolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz-Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., Rell-Bakalarska, M., and Maslinski, W. (2002). High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after antitumor necrosis factor alpha treatment. Arthritis Rheum., 46, 1744–1753.

    Article  CAS  PubMed  Google Scholar 

  • Zwerina, J., Hayer, S., Tohidast-Akrad, M., Bergmeister, H., Redlich, K., Feige, U., Dunstan, C., Kollias, G., Steiner, G., Smolen, J., and Schett, G. (2004). Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum., 50, 277–290.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology and Rheumatology, Hôpital Edouard Herriot, 69437, Lyon Cedex 03, France

    Pierre Miossec

Authors
  1. Pierre Miossec
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut National de Santé et de Recherche Médicale (INSERM), Paris, France

    Moncef Zouali

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Miossec, P. (2005). Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments. In: Zouali, M. (eds) Molecular Autoimmunity. Springer, Boston, MA. https://doi.org/10.1007/0-387-24534-0_23

Download citation

Publish with us

Policies and ethics

Search

Navigation